

# Leukemia & Lymphoma Management Test Selection Table

	Acute Myelocytic Leukemia (AML) Profile: Chromosome Analysis With Reflex to <i>FLT3</i> , <i>CEBPA</i> and <i>NPM1</i> * (511540)	B-cell Gene Rearrangements Profile, <i>IgH</i> and <i>IgK</i> * (481222); B-Cell, <i>IgH</i> Gene Rearrangements* (480716)	<i>BCL2-IgH</i> Gene Rearrangement* (480566)	<i>BCR-ABL1</i> Kinase Domain Mutation Analysis* (480510)	<i>BCR-ABL1</i> Transcript Detection for CML & ALL, Quantitative* (480481)	Chromosome Analysis, Leukemia/Lymphoma† (510999)	Chronic Myelogenous Leukemia (CML) Profile: Chromosome Analysis and <i>BCR-ABL</i> , <i>FISH</i> (150500)	CML <i>FISH</i> Reflex to <i>JAK2</i> <sup>V617F</sup> Mutation Analysis, Qualitative, With Reflex to <i>CALR</i> Mutation Analysis, <i>JAK2</i> Exon 12 Mutation Analysis and <i>MPL</i> Mutation Analysis (511595)	Fluorescence in situ hybridization ( <i>FISH</i> ), <i>Oncology</i> † (510669)	<i>JAK2</i> <sup>V617F</sup> Mutation Analysis, Qualitative, With Reflex to <i>CALR</i> Mutation Analysis, <i>JAK2</i> Exon 12 Mutation Analysis and <i>MPL</i> Mutation Analysis (489395)	Leukemia/Lymphoma Immunophenotyping Profile‡ (480260)	<i>PML-RARA</i> Transcript Detection for Acute Promyelocytic Leukemia, Quantitative* (510840)	SNP Microarray – Oncology (Revea®) (510146)	T-Cell Receptor $\gamma$ -Chain Gene Rearrangements (480708) and T-Cell Receptor $\beta$ -Chain Gene Rearrangements* (480985) T-Cell Receptor Gene Rearrangement Profile, $\gamma$ and $\beta$ (481080)
Aggressive B-cell lymphoma/non-Hodgkin lymphoma		●	●			●			1					
Acute lymphoblastic leukemia/lymphoma/lymphoblastic lymphoma		●				●			2		●		●	●
Acute myeloblastic leukemia (AML)	●					●			1		●		●	
Acute promyelocytic leukemia (APL)	●					●					●	●		
Adult T-cell leukemia/lymphoma (ATLL)						●			●		●		●	●
Anaplastic large-cell lymphoma									●		●			
Chronic lymphocytic leukemia (CLL)/lymphocytosis		●				3			1		●		●	●
Chronic myelogenous leukemia (CML)				4	5	●	●	●	●		●			
Cutaneous T-cell lymphoma (CTCL)						3					●			●
Hairy cell leukemia											●			
Hodgkin lymphoma <sup>§</sup>														
Lymphoblastic lymphoma (blood/bone marrow)/ALL		●				●			●		●		●	●
Lymphocytosis/chronic lymphocytic leukemia (CLL)		●				3			1				●	●
Mastocytosis									●					
MPN with eosinophilia (HES, CMML, EMS/SCLL), <i>FISH</i>									1					
Multiple myeloma/plasma cell leukemia		●				●			1		●		●	
Myelodysplastic syndrome (MDS)						●			1		●		●	
Myelofibrosis						●				●	●		●	
non-Hodgkin lymphoma		●	●			●			●		●			
Polycythemia vera						●		●	●	●	●		●	
Prolymphocytic leukemia		●				●					●		●	●
Sézary syndrome											●			●
T- $\gamma$ lymphoproliferative disease						●					●			●
Thrombocythemia, essential (ET)						6		●	6	●	●		●	

Additional Published Assays	Test No°
<i>CEBPA</i> Mutation Analysis*	489170
cKIT Mutation Analysis in Tumors of Hematopoietic Tissue*	480940
<i>FLT3</i> Internal Tandem Duplication (ITD) and D835 Variant Detection by PCR*	910040

Additional Published Assays	Test No°
<i>JAK2</i> <sup>V617F</sup> Mutation Analysis, Qualitative*‡	489200
<i>MPL</i> Mutation Analysis*	489150
<i>NPM1</i> Mutation Analysis*	489140

\*Molecular oncology †Cytogenetics and *FISH*  
‡Immunophenotyping by flow cytometry  
§There are no molecular/cytogenetic markers for HL.

1 Profile (*FISH*) available.  
2 Adult and pediatric profile (*FISH*) available.

3 Aided by T- or B-cell-specific mitogenic stimulation. 5 For post-treatment monitoring.  
4 CML, relapse on imatinib mesylate (Gleevec®). 6 Only to differentiate from CML.